SEATTLE (March 29, 2026) Freshly published, peer-reviewed findings from observational clinical research show that ID Genomics’ “bacterial fingerprinting” technology could sharpen antibiotic prescribing, cutting prescription errors and curbing overuse of broad-spectrum [...]
ID Genomics will present its pitch in MedTech Innovators’ lightning round on March 15th. Thanks to Wings and Life Sciences Washington for the opportunity! MedTech Innovator [...]
ID Genomics will present a booth advertising its genomics’ Services at Alliance Northwest (http://alliancenorthwest.org). We have been proudly offering Services such as 16S rRNA typing, MultiLocus Sequence Typing, antibiotic susceptibility testing, and Staphylococcus aureus SPA typing to [...]
IDG will present its work at the 13th Annual NIH CAP FeedForward(TM) Sessions. We thank the LARTA Institute for this opportunity and welcome mentor feedback! http://www.larta.org [...]
Modern Healthcare: Innovations has covered the Company’s novel approach to pairing the infecting bug with the right drug on the first try. Read the full text [...]
ID Genomics, Inc. has launched a first-of-its-kind initiative uniting clinical partners to fight antibiotic resistance around the world. GenomeWeb covered the news — read more about our efforts [...]
SEATTLE (January 11, 2026) ID Genomics, Inc. announced a national consortium of clinical partners aimed at making infectious disease diagnosis and antibiotic treatment faster and more accurate through the company’s novel DNA-based “bacterial fingerprinting” diagnostics [...]
ID Genomics’ CEO, Dr. Kaveri Parker, will present the Company’s technology and its implications for the American warfighter at the Defense Innovation Challenge in Austin, TX. Please come visit our showcase exhibit at booth 313W in Griffin Hall at the JW Marriott. [...]
As the recipient of a $3 million, 3-year Phase II SBIR grant, ID Genomics has been selected for the Commercialization Acceleration Program sponsored by the National Institutes of Health and the Larta Institute. The goal of this program is to assist early stage companies in commercializing their [...]
ID Genomics, Inc. has been selected as an Innovation Challenge company by the Redefining Early Stage Investments (RESI) Conference in Boston, MA. Please come visit our poster and learn more about the conference here: [...]